Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | TOP2A | P11388 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9757380 | 0.88 | KDM4E (0.64) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL10879645 | 0.86 | KDM4E (0.62) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL501238 | 0.85 | KDM4E (0.69) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL29442121 | 0.85 | KDM4E (0.69) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL10671868 | 0.84 | KDM4E (0.55) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL14159326 | 0.84 | KDM4E (0.82) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL9145542 | 0.84 | KDM4E (0.82) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL10874938 | 0.84 | KDM4E (0.62) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL4145110 | 0.83 | KDM4E (0.64) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| SCHEMBL16077976 | 0.83 | KDM4E (0.80) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4727080-A | BACTERICIDES, FUNGICIDES | PROVESAN S.A. (CH) | 1988-02-23 | — | — | US | claimed |
| EP-2293778-B1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND MOMETASONE | INTERVET INT BV (NL) | 2013-09-18 | — | — | EP | disclosed |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INC. | 2012-02-23 | — | — | US | disclosed |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INC. | 2012-02-23 | — | — | US | disclosed |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL BV | 2010-04-08 | — | — | US | disclosed |
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL BV | 2010-04-08 | — | — | US | disclosed |
| US-20090306035-A1 | Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest | EMORY UNIVERSITY (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306035-A1 | Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest | EMORY UNIVERSITY (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009147144-A2 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | INTERVET INTERNATIONAL B.V. (NL) | 2009-12-10 | — | — | WO | disclosed |
| US-4727080-A | BACTERICIDES, FUNGICIDES | PROVESAN S.A. (CH) | 1988-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087409-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | CYP21A2, CYP27A1, NR3C2 | KDM4E 3174/4885ALDH1A1 1287/4885LMNA 1358/4885 |
| US-20120046259-A1 | COMPOSITION COMPRISING AN ANTIBIOTIC AND A CORTICOSTEROID | CYP21A2, CYP27A1, NR3C2 | KDM4E 3174/4885ALDH1A1 1287/4885LMNA 1358/4885 |
| US-20090306035-A1 | Compounds and Methods for modulating the Silencing of a Polynucleotide of Interest | SNRPE, NSUN2, SNRPA | KDM4E 3182/4885ALDH1A1 3615/4885LMNA 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.